Measurement of N-terminal proatrial natriuretic peptide in plasma of cats with and without cardiomyopathy
| Autor: | Ingo Nolte, Felix Meneses, Tanja M. Zimmering, D. Simon |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Cardiomyopathy Enzyme-Linked Immunosorbent Assay Cat Diseases Internal medicine Blood plasma Natriuretic peptide Medicine Animals Protein Precursors N-terminal proatrial natriuretic peptide Heart Failure CATS General Veterinary business.industry General Medicine Venous blood medicine.disease Echocardiography Heart failure Cardiology Cats Radiography Thoracic business Cardiomyopathies Thoracic Radiography Atrial Natriuretic Factor |
| Zdroj: | American journal of veterinary research. 70(2) |
| ISSN: | 0002-9645 |
| Popis: | Objective—To determine whether plasma N-terminal proatrial natriuretic peptide (Nt-proANP) concentrations in cats with cardiomyopathy (CM) differ from values in healthy cats and evaluate whether plasma Nt-proANP concentrations can be used to discriminate cats with CM and congestive heart failure (CHF) from CM-affected cats without CHF. Animals—16 cats that had CM without CHF, 16 cats that had CM with CHF, and 11 healthy control cats. Procedures—All cats underwent a physical examination, assessment of clinicopathologic variables (including plasma thyroxine concentration), thoracic radiography, and echocardiography. On the basis of findings, cats were assigned to 1 of 3 groups (control cats, cats with CM and CHF, and cats with CM without CHF). Venous blood samples were obtained from all 43 cats, and plasma Nt-proANP concentrations were measured by use of a human proANP(1-98) ELISA. Results—Plasma Nt-proANP concentrations differed significantly among the 3 groups. Median Nt-proANP concentration was 381 fmol/mL (range, 52 to 450 fmol/mL), 763 fmol/mL (range, 167 to 2,386 fmol/mL), and 2,443 fmol/mL (range, 1,189 to 15,462 fmol/mL) in the control group, in cats with CM without CHF, and in cats with CM and CHF, respectively. Conclusions and Clinical Relevance—Measurement of plasma Nt-proANP concentration could be of benefit in the assessment of cats with naturally occurring CM and might have potential as a screening marker for the disease. Furthermore, measurement of plasma NtproANP concentration may be useful for distinguishing cats with CM and CHF from those with CM and no CHF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|